» Articles » PMID: 31546908

Design of Peptidomimetic Functionalized Cholesterol Based Lipid Nanoparticles for Efficient Delivery of Therapeutic Nucleic Acids

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2019 Sep 25
PMID 31546908
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Lipid nanoparticles (LNP) are the most potent carriers for the delivery of nucleic acid-based therapeutics. The first FDA approved a short interfering RNA (siRNA) drug that uses a cationic LNP system for the delivery of siRNA against human transthyretin (hTTR). However, preparation of such LNP involves tedious multi-step synthesis with relatively low yields. In the present study, we synthesized cationic peptidomimetic functionalized cholesterol (denote Chorn) in straightforward chemical approaches with high yield. When formulated with helper lipids, Chorn LNPs complexed with siRNA to form nanoparticles with an average diameter of 150 nm to 200 nm. Chorn LNP mediated transfection of a green fluorescence protein (GFP) expressing plasmid resulted in 60% GFP positive cells. Moreover, Chorn LNP delivered siRNA against polo-like kinase 1 (Plk1), a disease related gene in cancer cells and efficiently suppressed the expression of the gene, resulting in significant morphological changes in the cell nuclei. Our data suggested that cholesterol based cationic LNP, prepared through a robust chemical strategy, may provide a promising siRNA delivery system.

Citing Articles

mRNA vaccines as cancer therapies.

Huang S, Que H, Wang M, Wei X Chin Med J (Engl). 2024; 137(24):2979-2995.

PMID: 39668413 PMC: 11706586. DOI: 10.1097/CM9.0000000000003455.


Peptidomimetics in cancer targeting.

Gomari M, Abkhiz S, Pour T, Lotfi E, Rostami N, Nafe Monfared F Mol Med. 2022; 28(1):146.

PMID: 36476230 PMC: 9730693. DOI: 10.1186/s10020-022-00577-3.


Microfluidic-Based Cationic Cholesterol Lipid siRNA Delivery Nanosystem: Highly Efficient In Vitro Gene Silencing and the Intracellular Behavior.

Zhu Z, Zhang L, Sheng R, Chen J Int J Mol Sci. 2022; 23(7).

PMID: 35409359 PMC: 8999516. DOI: 10.3390/ijms23073999.


Silencing of STAT3 via Peptidomimetic LNP-Mediated Systemic Delivery of RNAi Downregulates PD-L1 and Inhibits Melanoma Growth.

Ehexige E, Bao M, Bazarjav P, Yu X, Xiao H, Han S Biomolecules. 2020; 10(2).

PMID: 32059541 PMC: 7072202. DOI: 10.3390/biom10020285.

References
1.
Aagaard L, Rossi J . RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007; 59(2-3):75-86. PMC: 1978219. DOI: 10.1016/j.addr.2007.03.005. View

2.
van der Meer R, Song H, Park S, Abdulkadir S, Roh M . RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition. Clin Cancer Res. 2014; 20(12):3211-21. PMC: 4086184. DOI: 10.1158/1078-0432.CCR-13-3116. View

3.
Xiao H, Altangerel A, Gerile G, Wu Y, Baigude H . Design of Highly Potent Lipid-Functionalized Peptidomimetics for Efficient in Vivo siRNA Delivery. ACS Appl Mater Interfaces. 2016; 8(12):7638-45. DOI: 10.1021/acsami.5b12144. View

4.
Caplen N, Alton E, Middleton P, Dorin J, Stevenson B, Gao X . Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med. 1995; 1(1):39-46. DOI: 10.1038/nm0195-39. View

5.
Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M . Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004; 432(7014):173-8. DOI: 10.1038/nature03121. View